Ernexa Therapeutics Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Cambridge, MA
ERNA chart
What traders are saying about $ERNA
Latest postsErnexa Therapeutics Inc. news
- Ernexa Therapeutics Inc. Estimates – NASDAQ:ERNA
TradingView ·
- Ernexa Therapeutics Inc. (ERNAW) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Ernexa Therapeutics advances ERNA-101 cell ther...
Pluang ·
- Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Yahoo Finance ·
- Ernexa Therapeutics Highlights ERNA-101’s Path Toward the
GlobeNewswire ·
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Yahoo Finance ·
- Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Yahoo Finance ·
- Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Yahoo Finance ·
- Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Yahoo Finance ·
- Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Yahoo Finance ·
- Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Yahoo Finance ·
- Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
Yahoo Finance ·
Ernexa Therapeutics Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $582,000 | $68,000 | $0 |
| Net income | -$14.1M | -$44.5M | -$21.7M | -$24.6M |
| Diluted EPS | $-2.24 | $-48.96 | $-4.08 | $-8.06 |
| Total assets (year end) | $5.8M | $5.3M | $49.1M | $22.3M |
| Cash and equivalents (year end) | – | $1.7M | $7.6M | $11.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Ernexa Therapeutics Inc.
- Ticker
- ERNA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 748592
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC
Frequently asked questions
What exchange is Ernexa Therapeutics Inc. listed on?
Ernexa Therapeutics Inc. trades on the Nasdaq under the ticker symbol ERNA.
What industry is Ernexa Therapeutics Inc. in?
Ernexa Therapeutics Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Ernexa Therapeutics Inc. headquartered?
Ernexa Therapeutics Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Ernexa Therapeutics Inc.'s fiscal year end?
Ernexa Therapeutics Inc.'s fiscal year ends on December 31.
How much revenue did Ernexa Therapeutics Inc. report?
Ernexa Therapeutics Inc. reported $582,000 in revenue for calendar year 2024, according to its SEC filings.